March 2014 in “Journal of The American Academy of Dermatology” Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
26 citations
,
October 2019 in “JNCI Cancer Spectrum” Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.
188 citations
,
October 2014 in “Thyroid” Dabrafenib was effective and well tolerated in treating thyroid cancer with a specific mutation.
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
March 2014 in “Journal of The American Academy of Dermatology” Vitamin D deficiency is common in temporary hair loss, and stress is often a suspected cause.
Robotic-assisted hair transplant is effective and less painful, but needs more evaluation for long-term results.
January 2026 in “Frontiers in Public Health” Baricitinib and tofacitinib have different safety patterns in treating alopecia areata.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
39 citations
,
January 2019 in “Journal of Dermatological Treatment” Ketoconazole cream is effective for skin conditions like seborrheic dermatitis and may help with hair loss and other skin issues, with generally mild side effects.
Elderly skin care needs personalized treatment, early intervention, and integrated psychiatric care.
September 2025 in “Cermin Dunia Kedokteran” Candida nail infections need lab tests for accurate diagnosis and treatment.
The document is a detailed guide on skin conditions and treatments for dermatologists.
March 2014 in “Journal of The American Academy of Dermatology” The document lists various dermatology topics, treatments, and diagnostic methods.
November 2025 in “Mendeley Data” Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
2 citations
,
September 2024 in “PLoS ONE” Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
May 2019 in “Journal of clinical oncology” Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
December 2023 in “Journal of ethnopharmacology” Tribuloside can increase skin pigmentation by enhancing melanin production and distribution.
5 citations
,
March 2021 in “Hepatitis Monthly” Tenofovir alafenamide fumarate is effective and safer for hepatitis B, with fewer side effects than tenofovir disoproxil fumarate.
21 citations
,
March 2015 in “Journal of The American Academy of Dermatology” Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
30 citations
,
December 2019 in “PLoS ONE” The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.
January 2025 in “The Egyptian Journal of Hospital Medicine” Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.